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CD147,asareceptorforCyclophilins,isamultifunctionaltransmembraneglycoprotein.Inordertoidentifygenesthatareinduced
by activation of CD147, THP-1 cells were stimulated with Cyclophilin A and diﬀerentially expressed genes were detected using
PCR-based analysis. Interferon-induced transmembrane 1 (IFITM1) was detected to be induced and it was conﬁrmed by RT-PCR
and Western blot analysis. CD147-induced expression of IFITM1 was blocked by inhibitors of ERK, PI3K, or NF-κB, but not by
inhibitors of p38, JNK, or PKC. IFITM1 appears to mediate inﬂammatory activation of THP-1 cells since cross-linking of IFITM1
with speciﬁc monoclonal antibody against it induced the expression of proinﬂammatory mediators such as IL-8 and MMP-9.
These data indicate that IFITM1 is one of the pro-inﬂammatory mediators that are induced by signaling initiated by the activation
of CD147 in macrophages and activation of ERK, PI3K, and NF-κB is required for the expression of IFITM1.
1.Introduction
Interferon-induced transmembrane (IFITM/Mil/fragilis)
proteins, originally described based on their expression
after IFN treatment [1], belong to a superfamily that
is characterized by the presence of two transmembrane
domains and an intervening highly conserved intracellular
loop. Over 30 members of this superfamily are known to
be involved in antiviral defense, immune cell signaling,
cell adhesion, oncogenesis, and germ cell maturation
[2–6]. As the ﬁrst identiﬁed member of this superfamily,
IFITM1 (CD225) has been studied for its involvement in the
inhibition of viral replication [7], promotion of cancer cell
invasion [8], and expression in transformed cells as a cancer
marker [9–12].
CD147 (EMMPRIN/basigin/HAb18G/neurothelin/M6/
TCSF) has two immunoglobulin-like extracellular domains
and a short (39 amino acids long) intracellular domain
[13]. CD147 plays a critical role in many pathological and
physiological processes in a variety of cell types such as
cancercells,leukocytes,ﬁbroblasts,andendothelialcells[14–
17]. Stimulation of CD147 in ﬁbroblast and endothelial cells
has been shown to facilitate tumor invasion, metastasis,
and angiogenesis [17, 18]. On the other hand, stimulation
of CD147 in leukocytes leads to the enhancement of
a variety of inﬂammatory processes that are associated
with atherosclerosis, lung injury, rheumatoid arthritis (RA),
chronic liver disease, and heart failure [19–21]. Two mem-
bers of cyclophilin family, cyclophilin A and B (CypA and
CypB), can interact and stimulate CD147 [22, 23]. These
cyclosporine binding proteins can be secreted in response to
inﬂammatory stimuli. CypA can be secreted from activated
platelets, smooth muscle cells (SMCs), and macrophages
[24–26]. CypA exerts cytokine-like activities [25, 27]w h i c h
has been recognized in the pathogenesis of various diseases
including rheumatoid arthritis [28–30], sepsis [31, 32], and
atherosclerosis [21, 25, 27, 33, 34]. CypB is known to be
present in the ER of all cell types and is involved in various
functions such as chemotaxis, hepatitis C virus replication,
immunosuppression, prolactin signaling, and association
with collagen [35–40]. CypB has been found to be present in
humanblood,milk,andculturesupernatantofchondrocytes
[41, 42], suggesting that it can also be secreted.
In order to identify molecules which are induced by the
stimulation of CD147, the human macrophage-like cell line,
THP-1, was stimulated with CypA. IFITM1 was identiﬁed2 Mediators of Inﬂammation
to be one of the molecules that are induced by CypA.
Signaling pathways responsible for the expression of IFITM1
a n dp o s s i b l er o l eo fI F I T M 1i nm a c r o p h a g ea c t i v i t yw e r e
investigated.
2.MaterialsandMethods
2.1. Monoclonal Antibodies, Cell Lines, and Reagents. Recom-
binant human CypA was purchased from BIOMOL Inter-
national (USA). mAb for CD147 (clone MEM-M6/1) was
from Abcam (MA, USA) anti-IFITM1 mAb was purchased
from Abnova. PD08059 and U0126 were originated from
Cell Signaling (USA); SB203580, Ro-31-8425, JNK inhibitor
I (JNK-I1), a cell-permeable fusion protein containing 20
AA of the JNK-binding domain of islet-brain and HIV-
TAT48–57 [43], and its negative control containing only
HIV-TAT were obtained from Calbiochem International
Inc. (USA), LY294002 were purchased from Sigma. α-actin
speciﬁc mAb (1A4) was purchased from DAKO (Glostrup,
Denmark). Human monocytic leukemia cell line THP-1 [44]
was obtained from the American Type Culture Collection
(USA).
2.2. Gene Fishing Analysis. Diﬀerentially expressed genes
(DEGs) were screened by the annealing control primer-
(ACP)-based PCR method using the GeneFishing DEG
kits (Seegene, Seoul, South Korea) according to a protocol
provided from the manufacturer [11]. The ampliﬁed PCR
products were separated in 2% agarose gel stained with
ethidium bromide. The diﬀerentially expressed bands were
extracted from the gel using the GENCLEAN II Kit (Q-
BIO gene, Carlsbad, CA), cloned into a TA cloning vector
(Invitrogen, Karlsruhe, Germany) and sequenced. Resulting
sequences were compared with GenBank database using the
Basic Local Alignment Search Tool (BLAST) search program
at the National Center for Biotechnology Information [12].
2.3. RT-PCR. Five micrograms of total RNAs isolated
f r o mc e l l sw e r et r e a t e dw i t hR N a s ef r e eD N a s e( B D -
Pharmingen), and then used to generate ﬁrst-strand
cDNAs using RevertAid ﬁrst-strand cDNA synthesis
kit with 500ng oligo (dT)12–18 primers. PCR primers
were designed with ABI PRISM Primer Express 2.0
(Applied Biosystems) and made by Geno Tech Corp
(Korea). For real time RT-PCR reactions, primers were
designed for 195bp, 65bp, and 51bp of IFITM1, IFI27,
and GAPDH PCR products. Primer sequences were
5 tcatcctgtcactggtattcggctc3 (forward) and 5 gtgggtataaac-
tgctgtatctaggg3  (reverse) for IFITM1, 5 tctgcagtcactggg-
agcaa3  (forward) and 5 cccaatgga gcccaggat3  (reverse)
for IFI27 and 5 tgggctacactgagcaccag3  (forward) and
5 gggtgtcgctgttgaagtca3  (reverse) for human GAPDH.
Real-time PCR reaction was performed in ABI PRISM 7300
sequence detector (Applied Biosystems) using SYBR green
PCR mix (Applied Biosystems) with cDNA corresponding
to 125ng of original total RNA and 400nM primers in a
20μL volume. The threshold cycle (Ct) values for IFI27
and IFITM1 reactions were normalized with Ct value from
GAPDH reactions. The speciﬁcity of the PCR reaction
1
2
GP1 GP2 GP3 GP4
− + − + − + − + CypA
1k b
0.5 kb
Figure 1:GeneFishinganalysisafterCypAtreatment inTHP-1cells
revealed multiple diﬀerentially expressed genes. THP-1 cells were
treated with or without 0.1μMo fC y p A .T o t a lc e l l u l a rR N A sw e r e
isolated 20hr after stimulation and diﬀerentially expressed gene
(DEG) levels were analyzed by PCR using 20 diﬀerent ACS random
primer sets (GP1 through GP20). Results for GP1 through GP4
are shown in the ﬁgure. White boxes indicate the bands that were
analyzed for identiﬁcation through cloning and sequencing.
was conﬁrmed by control reactions such as PCR reaction
with templates processed without reverse transcriptase and
PCR reaction without template. For conventional RT-PCR
analysis same process was used for the preparation of
cDNA. Primers were designed for 412bp, 397bp, and 391bp
of IFITM1, IFI27, and GAPDH PCR products. Primer
sequences were 5 ttcactcaacacttccttcc3  (forward) and
5 actagtaaccccgtttttcc3  (reverse) for IFITM1, 5 actctggaa-
tgccacggaat3  (forward) and 5 gagctagtagaacctcgcaacccaa3 
(reverse) for IFI27 and 5 atcactgccacccagaagac3  (forward)
and 5 tgagcttgacaaagtggtcg3  (reverse) for human GAPDH.
After the PCR reaction, the PCR products were run on
2% agarose gel to conﬁrm the size and purity of the PCR
products.
2.4. Cell Stimulation, Western Blot Analysis, and Gelatin
Zymogram. THP-1 cells were stimulated by adding 1μM
of recombinant human CypA or adding 1–30μg/mL anti-
CD147 or anti-IFITM1 mAb in a soluble form. Cell lysates
were prepared at appropriate times after activation in 100μL
of triple-detergent lysis buﬀer. Western blot analysis was
performed as described previously in [45]. For the detection
of MMP-9 using gelatin zymogram, culture supernatants
were collected 24 hours after activation. The MMP-9 activity
in the culture supernatant was determined by substrate gel
electrophoresis as described previously in [46].
2.5. Statistical Analysis. Statistical signiﬁcance of diﬀerences
was evaluated by means of a two-sided Student’s t-test,
assuming equal variances. Diﬀerences were considered sig-
niﬁcant when P<. 05.
3. Results and Discussion
3.1. GeneFishing Analysis Identiﬁed IFITM1 as One of the
P r o t e i n st h a tA r eI n d u c e da f t e rC y p AT r e a t m e n ti nT H P -
1C e l l s .Treatment with CypA has been shown to be able
to stimulate THP-1 cells resulting in the production ofMediators of Inﬂammation 3
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Figure 2: Stimulation of THP-1 cells with CypA induced the expression of IFI27 and IFITM1. (a) THP-1 cells were stimulated with 0.1μM
of CypA for 20hr. Total cellular RNA was then isolated for real-time RT-PCR with primers speciﬁc for IFI27, IFITM1, or GAPDH. Ct values
obtained from IFI27 or IFITM1 ampliﬁcation curves were normalized with that of GAPDH. (b) THP-1 cells were stimulated and cellular
RNAs were isolated as in (a). RT-PCR analysis was performed with primers speciﬁc for IFI27, IFITM1, or GAPDH and the products were
run on agarose gel. These experiments were repeated three times with essentially the same results.
proinﬂammatory mediators such as MMP-9, IL-8, TNF-α,
MCP-1, and IL-1β [28]. In order to identify genes that are
expressed by CypA treatment, THP-1 cells were stimulated
with CypA for 24 hours and the genes showing diﬀerential
expression patterns were detected using GeneFishing diﬀer-
entially expressed gene (DEG) system. Total RNA extracted
from THP-1 cells stimulated with or without CypA were
used for the synthesis of cDNA. DEGs were screened by an
annealing control primer-based PCR method [47]. Twenty
diﬀerent primer sets were tested which revealed multiple
bands with diﬀerential expression patterns. Two of these
bands (Figure 1, number 1 and 2) were extracted and
sequenced for the identiﬁcation of the corresponding genes.
Band number 1 was identiﬁed to be homosapiens interferon,
alpha-inducible protein 27 (IFI27) (gene bank accession
number BC015492) and band number 2 was identiﬁed
to be human interferon-inducible protein 9–27 (IFITM1)
(gene bank accession number J04164). The expression of
both IFI27 and IFITM1 is previously known to be induced
by interferon. In order to conﬁrm the expression of these
genes, RT-PCR analysis was performed after stimulation
of THP-1 cells with CypA (Figure 2). Both real-time and
conventional RT-PCR demonstrated the induction of both
IFI27 and IFITM1 after CypA treatment. In case of IFI27,
basalexpressionlevelswerenotdetectablewhilethelowbasal
expression of IFITM1 was detected.
3.2. Stimulation of CD147 with Monoclonal Antibodies Also
Activated the Expression of IFITM1 in THP-1 Cells. CypA
is known to exert its activity through its interaction with
CD147. CD147 expression has been detected in various
cell types including cancer cells, leukocytes, ﬁbroblasts, and
endothelial cells, and the stimulation of macrophage CD147
with either CypA or anti-CD147 mAb generated cell signal-
ing which was mediated by PI3K and/or ERK [14–17, 29, 33,
48, 49]. Activation of these signaling mediators eventually
leads to the activation of NF-κB, the major proinﬂamma-
tory transcription factor. Activation of macrophage CD147
resulted in the induction of the expression of various genes
including cytokine genes and matrix degrading enzymes. In
order to demonstrate that the stimulation of CD147 induces
the expression of IFITM1, THP-1 cells were stimulated with4 Mediators of Inﬂammation
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Figure 3: Stimulation of THP-1 cells with anti-CD147 mAb induced the expression of IFITM1. (a) THP-1 cells were stimulated with
10μg/mL of anti-CD147 mAb for 24hr. Total cellular RNA was isolated, and RT-PCR analysis was performed with primers speciﬁc for
IFITM1, IFI27, and GAPDH. (b) THP-1 cells were stimulated with 10μg/ml of anti-CD147 mAb or isotype matching mouse IgG (control).
Cell lysates were obtained at indicated times for the Western blot analysis using mAbs speciﬁc for IFITM1 and actin. These experiments were
repeated more than three times with essentially the same results.
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Figure 4: Inhibitors of ERK, NF-κB, and PI3K blocked the CD147-mediated activation of IFITM1 expression. (a) THP-1 cells were
preincubated with 10μM of U0126 (U), 5μMo fT P C K( T ) ,0 . 2 %o fD M S O( D ) ,1 0μM of JNK inhibitor (JI), negative control of JNK
inhibitor (J(−)) for 30min, and 20μM of LY294002 (LY) or 1μM of Ro-31-8425 (Ro) for 60min and then stimulated with 10μg/mL of
anti-CD147 mAb for 48hr. Cell lysates were collected and subjected to Western blot analysis using mAbs speciﬁc to either IFITM1 or actin.
(b) THP-1 cells were stimulated with 10μg/mL of anti-CD147 mAb or mouse IgG (mIgG) for indicated times. Cell lysates were collected
and subjected to Western blot analysis using mAbs speciﬁc to either AKT or phosphor-AKT. These experiments were repeated twice with
essentially the same results.
anti-CD147mAb.IFITM1andIFI27expressionwasdetected
to be induced by anti-CD147 treatment through RT-PCR
(Figure 3(a))a sw e l la sW e s t e r nb l o ta n a l y s i s( Figure 3(b)).
Protein levels of IFITM1 started to be upregulated from 48
hours after activation and continued to increase up to 72hrs.
The clone of anti-CD147 mAb used in the current study
is somewhat unique in that it is able to stimulate CD147 to
induce signaling. The majority of anti-CD147 mAb clones,
however, tend to block the activation. It is possible that the
clone of antibody used in the current study may interactMediators of Inﬂammation 5
with an epitope that can induce conformational change in
the CD147 in such a way that it can activate downstream
signaling adaptors. It is also possible that cross-linkage
of CD147 that is induced by the current antibody may
result in an arrangement of downstream adaptor molecules
in such a way that facilitates generation of activation
signals.
3.3. The CD147-Mediated Expression of IFITM1 Required
E R Ka n dP I 3 Ka sS i g n a l i n gA d a p t o r sa n dN F - κBa saT r a n -
scription Factor. In order to ﬁnd out the signaling mediators
which are responsible for the CD147-mediated expression of
IFITM1, THP-1 cells were stimulated with anti-CD147 mAb
in the presence of the inhibitors for mitogen-activated pro-
tein kinase (MAPK), PKC, PI3K, and NF-κB. There are three
members of MAPK family: ERK, p38, and JNK. As shown
in Figure 4(a), an inhibitor for ERK (U0126) blocked the
CD147-mediated activation of IFITM1 while JNK inhibitor
did not. Lim et al. reported that CD147-mediated induction
of MMP-1 in ﬁbroblasts is mediated by p38 [50]. However,
the activation p38 MAPK was not required in CD147-
mediated activation of IFITM1 because p38 inhibitor failed
to block the response (data not shown). Inhibitors of PI3K
(LY294002) and NF-κB (TPCK) also blocked the CD147-
mediated activation of IFITM1 while PKC inhibitor (Ro-31-
8425) did not (Figure 4(a)). The involvement of both ERK
and NF-κB has already been demonstrated in the induction
of MMP-9 expression in THP-1 cells after stimulation of
CD147 with either CypA or anti-CD147 mAb [29, 33].
Since activation of PI3K has not been reported previously,
it was conﬁrmed by analyzing the phosphorylation of AKT
(the main substrate of PI3K) using Western blot analysis.
As shown in Figure 4(b), stimulation of CD147 induced
phosphorylation of AKT within 30 minutes after activation
and the phosphorylation level peaked at 60 minutes after
activation. The phosphorylation of AKT was not detected
in control samples which are treated with mouse IgG for 30
and 60 minutes. These data indicates that CD147-induced
expression of IFITM1 requires activation of ERK, PI3K, and
NF-κB.
Both ERK and PI3K have been recognized as the
upstream signaling molecules involved in NF-κBa c t i v a t i o n
in macrophages. ERK is a well-known mediator of inﬂam-
mation and the ERK-mediated activation of NF-κBh a s
been implicated in the induction of both MMP-9 and IL-
8 in THP-1 cells that had been stimulated with agonistic
antibodies against the membrane bound form of GITRL, a
member of the tumor necrosis factor superfamily (TNFSF)
[51]. Furthermore, similar signaling pathway has been
observed in bovine glycomacropeptide-induced expression
o fI L - 8 ,T N F ,a n dI L - 1 β [52] and Cyclophilin A-induced
expression of MMP-9 [29]. On the other hand, there are
cases where ERK and PI3K separately activate NF-κB. These
include the serum amyloid A-induced activation of NF-
κB in peripheral blood mononuclear cells (PBMCs) and
THP-1 cells [53] and angiocidin-mediated activation of NF-
κB in THP-1 cells [54]. Based on these observations in
combinationwithourdata,itishighlylikelythattheCD147-
mediated activation of NF-κB occurs via two separate
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Figure 5: Crosslinking of IFITM1 induces the expression of MMP-
9 and IL-8 in THP-1 cells. (a) cells were stimulated with 1μg/mL of
LPS, 0.1, 1, 5, or 10μg/mL of anti-IFITM1 or 10μg/mL of isotype
matching mouse IgG. Culture supernatants were collected in 24hr
for the measurement of MMP-9 activity using gelatin zymogram.
(b) cells were stimulated with 1μg/mL of LPS, 10μg/mL of anti-
IFITM1orisotypematchingmouseIgG.HI:heatinactivation,95◦C
for 2hr. (c) cells were stimulated with 1μg/mL of LPS, 0.1, 1, 5,
10, or 30μg/mL of anti-IFITM1 or 30μg/mL of isotype matching
mouse IgG. Culture supernatants were collected in 24hr for the
measurement of IL-8 concentration using ELISA. (d) and (e) cells
were stimulated with 1μg/mL of LPS (L), 30μg/mL of anti-IFITM1
(I) or 30μg/mL of isotype matching mouse IgG (M). Culture
supernatants were collected in 24hr for the measurement of MCP-1
(d) and TNF-α (e) concentrations using ELISA. C: control. These
experiments were repeated more than three times with essentially
the same results.
pathways, one involving ERK and the other involving
PI3K.
3.4. The Stimulation of IFITM1 on the Surface of THP-1
Cells Also Induced Proinﬂammatory Responses. Involvement
of similar signaling molecules for the expression of MMP-96 Mediators of Inﬂammation
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Figure 6: IFITM1-mediated induction of MMP-9 expression requires ERK, PI3K, and NF-κB in THP-1 cells. (a) cells were preincubated
with indicated concentrations of TPCK or JNK inhibitor or 10μM of negative control for JNK inhibitor (J(−)) for 30min. Cells were then
stimulated with 1μg/mL of LPS or 10μg/mL of anti-IFITM1 mAb for 24hrs, and culture supernatants were collected for the measurement
of MMP-9 activity using gelatin zymogram. (b) cells were preincubated with 10μM of U0126 (U), SB203580 (SB), or LY294002 (LY) for
30min. DMSO (D, 0.1%) was used as a vehicle control. Cells were then stimulated with 10μg/mL of anti-IFITM1 mAb for 24hr and MMP-9
activity was tested as in (a). These experiments were repeated twice with essentially the same results.
and IFITM1 raise the possibility that IFITM1 may also have
proinﬂammatory function. In order to test that possibility,
IFITM1 expressed on THP-1 cells were cross-linked with
speciﬁc mAb. As shown in Figure 5(a),t r e a t m e n tw i t h
anti-IFITM1 mAb induced the expression of MMP-9 in
a dose-dependent manner while same amount of isotype
matching mouse IgG did not. The expression of MMP-9 and
cytokines from macrophages may have caused by endotoxin
which easily contaminate antibody preparations. In order to
exclude the possibility of endotoxin contamination, the anti-
IFITM1 mAb preparation was treated with heat to inactivate
the antibody structure. As shown in Figure 5(b), heat inac-
tivation abolished the stimulatory activity of anti-IFITM1
mAb, thus excluding the possibility of contamination with
endotoxin which is heat resistant. Furthermore, stimulation
of THP-1 cells with IFITM1 induced expression of IL-8 in a
dose dependent manner and treatment with 30μg/mL of the
antibody induced the highest response (Figure 5(c)). At the
same concentration of antibody treatment, the expression of
other cytokines such as MCP1 and TNF-α was also induced
(Figures 5(d) and 5(e)). These data indicate that IFITM1
induces proinﬂammatory responses upon stimulation and
cytokines and matrix degrading enzymes are the mediators
that can be induced by the activation of IFITM1.
In order to investigate the signaling pathway induced by
IFITM1,THP-1cellswerestimulatedwithanti-IFITM1mAb
in the presence of various inhibitors of signaling adaptors.
As shown in Figure 6, U0126 (ERK inhibitor) blocked the
expression of MMP-9 while SB203580 (p38 inhibitor) or
JNK inhibitor failed. Treatment with JNK inhibitor, but not
with its negative control, tended to enhance the response.
This indicates that there could be an interplay between JNK
and ERK in IFITM1-mediated cell signaling. Additionally,
LY294002 (PI3K inhibitor) blocked the expression of MMP-
9. NF-κB is the major transcription factor involved in the
expression of MMP-9 during inﬂammatory activation of
macrophages. When TPCK (NF-κB inhibitor) was treated
at the same condition, the induction of MMP-9 expression
was blocked. These data indicates ERK and PI3K are the
downstream mediators of IFITM1-induced signaling in
THP-1 cells and activation of these signaling adaptors then
leads to the activation of NF-κB for the transcriptional
activation of the MMP-9 genes. The involvement of ERK
or PI3K in the activation of NF-κBh a sb e e nd o c u m e n t e d
previously. ERK is a well-known mediator of inﬂammation
and has been demonstrated to be activated in THP-1 cells
after inﬂammatory activation [29, 51, 52]. On the other
hand, involvement of both ERK and PI3K in the activation
of NF-κB has been shown after stimulation of THP-1 cells
with serum amyloid A [53] or angiocidin [54].
In hepatocytes, IFITM1 has been reported to be asso-
ciated with caveolin-1 and this association enhanced the
inhibitory action of caveoin-1 on ERK activation [55]. This
discrepancy in the action of IFITM1 with regard to the ERK
activity may have been caused by the diﬀerence in cell types.
It is possible that diﬀerent adaptor molecules are associated
withtheintracellularregionofIFITM1indiﬀerentcelltypes.
ItisalsopossiblethattheassociationbetweenIFITM1andits
adaptors is eﬀected by the activation status of the cells.
Previous data indicated that the stimulation of CD147
also induces the expression of MMP-9 in THP-1 cells
through ERK [33]. It is interesting that the CD147-mediated
induction of MMP-9 expression and IFITM1-mediated
MMP-9 expression use same signaling adaptors in THP-1
cells. In order to test whether stimulation of CD147 and
IFITM1 at the same time induces a synergistic expression
of MMP-9, THP-1 cells were cotreated with mAbs against
these molecules. Simultaneous treatment with these agents,
however, failed to induces any synergistic expression of
MMP-9 (data not shown). It appears that the addition of one
of these agents already induce maximal levels of MMP-9 and
cotreatment may not induced further activation since these
agents use the same signaling pathway for the induction of
MMP-9.Mediators of Inﬂammation 7
Our data provide the ﬁrst evidence which demon-
strates the proinﬂammatory activities of IFITM1. Previously,
IFITM1hasbeenreportedtobeenhancingtheinvasiveactiv-
ity of cancer cells, but the underlying mechanism has not
been elucidated [8]. It is possible that the IFITM1-mediated
induction of MMP-9 expression and subsequent degra-
dation of extracellular matrix proteins are the molecular
mechanism responsible for the enhancement of cancer cell
invasion.
4. Conclusion
Although CD147 has been implicated in various biological
processes associated with normal and pathologic conditions,
the exact role of it is not well known at the molecular level,
exceptinafewcases.Inmyeloidcellsincludingmacrophages,
CD147 is expressed at high levels and stimulation of it
induces strong inﬂammatory responses such as production
of proinﬂammatory mediators, especially matrix degrading
enzymes [28, 33, 56]. In THP-1 cells, high basal level expres-
sion of CD147 was detected and treatment with either CypA
or anti-CD147 mAb induced expression of inﬂammatory
mediators such as cytokines and matrix degrading enzymes
[21, 28, 56] .T h e s ea c t i v i t i e so fC D 1 4 7a r ee x p e c t e dt o
contribute to the pathogenesis of various diseases where
macrophage inﬂammatory responses play essential roles. In
chronic inﬂammatory diseases such as atherosclerosis, the
generation of foamy macrophages is responsible for the
formation of fatty streak, the hallmark of the disease [57].
Later, these cells are the main cell type responsible for the
formation of atherosclerotic plaques and plaque rupture
which leads to the occurrence of acute myocardial infarction
[58]. Immunohistochemical analysis revealed the high level
expression of CD147 in macrophages in atherosclerotic
plaques [33, 34]. CD147 is expected to contribute to the
inﬂammatory activation of macrophages during the patho-
genesis of atherosclerosis. Our data provides evidences that
IFITM1 is one of the molecules that are induced after CD147
activation. Further analysis demonstrated that IFITM1
itself may perform proinﬂammatory activities by activating
cytokines and matrix degrading enzymes. These data indi-
cate that there are cascade of inﬂammatory signal where one
stepofinﬂammatoryactivationinvolvingCD147isampliﬁed
into next round of proinﬂammatory cycle where much
high number of proinﬂammatory mediators, which includes
IFITM1, are activated. These vicious cycles of inﬂammatory
cascade are believed to be eﬀective in other diseases where
macrophage inﬂammatory activation is involved. Clearly,
development of the therapeutic target for the treatment of
these chronic inﬂammatory diseases requires a concoction
of ways to sever this vicious cycle at the early stages of its
ampliﬁcation.
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